Because particular chemotherapies may regulate inhibitory ligand expression through distinct pathways that may be time-, concentration- and tumor-specific, additional studies are required to better understand the mechanisms of chemotherapy-induced PD-L1/L2 and CTLA-4 expression in aberrant cells and its potential relevance to adjuvant antibody and immune therapies. Here, CD274 is linked to neoplasm.